<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the pathobiology of the non-Hodgkin lymphomas
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the pathobiology of the non-Hodgkin lymphomas
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the pathobiology of the non-Hodgkin lymphomas
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer R Brown, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arnold S Freedman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Lister, MD, FRCP, FRCPath, FRCR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Non-Hodgkin lymphoma (NHL) consists of a diverse group of malignant tumors of the lymphoid tissues variously derived from the clonal expansion of B cells, T cells, natural killer (NK) cells or precursors of these cells. This topic will review the most common mechanisms underlying the pathobiology of the NHLs.
        </p>
        <p>
         Specifics regarding the pathobiology of the more common lymphoma subtypes are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse large B cell lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">
          "Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mantle cell lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4725.html" rel="external">
          "Pathobiology of mantle cell lymphoma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Burkitt lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4723.html" rel="external">
          "Pathobiology of Burkitt lymphoma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small lymphocytic lymphoma/chronic lymphocytic leukemia (see
         <a class="medical medical_review" href="/z/d/html/4539.html" rel="external">
          "Pathobiology of chronic lymphocytic leukemia"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Follicular lymphoma (see
         <a class="medical medical_review" href="/z/d/html/16646.html" rel="external">
          "Pathobiology of follicular lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16646.html" rel="external">
          "Pathobiology of follicular lymphoma", section on 'Introduction'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoplasmacytic lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4768.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma", section on 'Pathogenesis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extranodal marginal zone lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)", section on 'Pathogenesis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Splenic marginal zone lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4731.html" rel="external">
          "Splenic marginal zone lymphoma", section on 'Pathogenesis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4026474">
         <span class="h1">
          CELL OF ORIGIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphomas are derived from B and T lymphocytes or natural killer (NK) cells at varying stages of maturation, and many of the biologic features of these malignant cells reflect their normal counterparts. A cell of origin has been proposed for each type of NHL based on morphologic, immunophenotypic, and genetic features of the malignant cells. However, in many cases this is not clear cut. Some NHLs classified as the same NHL subtype may be derived from cells at different stages of maturation (eg, germinal center B cell like diffuse large B cell lymphoma versus activated B cell like diffuse large B cell lymphoma). Other NHL subtypes do not have an easily identified cell of origin (eg, hairy cell leukemia, chronic lymphocytic leukemia). (See
         <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">
          "Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'Gene expression heterogeneity of DLBCL'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4532.html" rel="external">
          "Clinical features and diagnosis of hairy cell leukemia", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         NK cells share immunophenotypic and functional features with gamma/delta T lymphocytes making the distinction between tumors derived from NK and gamma/delta T cells difficult. For cases in which this distinction is unclear, the term "NK/T cell" NHL is used (eg, extranodal NK/T cell lymphoma, nasal type).
        </p>
        <p class="headingAnchor" id="H38692429">
         <span class="h2">
          B cell lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         B cell lymphomas can arise at any stage of normal B cell development, but most are derived from cells that have been exposed to the germinal center reaction [
         <a href="#rid1">
          1
         </a>
         ]. Normal B cell development can be divided into three main stages (see
         <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">
          "Normal B and T lymphocyte development", section on 'B cell development'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pre-germinal center
         </strong>
         – Normal early B cell development takes place in the bone marrow and results in the transformation of a B progenitor cell (pre-pro B cell) into a mature B cell. Mature B cells have undergone immunoglobulin VDJ gene rearrangement and express a complete IgM antibody molecule on the cell surface. After release from the bone marrow, antigen-naïve mature B cells are exposed to antigen in the interfollicular area of the secondary lymphoid tissues (eg, lymph nodes, spleen). After this exposure, the majority migrate into the germinal center. A small population of antigen-naïve mature B cells circulates in the peripheral blood or resides in primary lymphoid follicles and follicle mantle zones. These cells provide the initial IgM antibody response  (
         <a class="graphic graphic_figure graphicRef51396" href="/z/d/graphic/51396.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Naïve mature B cells in the mantle zone are thought to give rise to mantle cell lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/4725.html" rel="external">
          "Pathobiology of mantle cell lymphoma", section on 'Cell of origin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Germinal center
         </strong>
         – Mature, antigen-exposed B cells proliferate in the center of a primary follicle among follicular dendritic cells to form a germinal center. These centroblasts mature into centrocytes as they transition into the light zone of the germinal center. In the germinal center, B cells undergo class-switch recombination (from IgM to IgG or IgA) and somatic hypermutation (to increase antibody affinity for antigen). In addition, the immunoglobulin heavy and light chain variable region genes and other genes that are off-targets for somatic hypermutation (eg, BCL-6) undergo mutation in the germinal center and act as markers of germinal center transit.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Centroblasts are thought to give rise to Burkitt lymphoma/leukemia and germinal center B cell (GCB) diffuse large B cell lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">
          "Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'Cell of Origin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4723.html" rel="external">
          "Pathobiology of Burkitt lymphoma", section on 'Cell of origin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Centrocytes are thought to give rise to follicular lymphoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Marginal zone B cells are thought to give rise to marginal zone lymphoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-germinal center
         </strong>
         – After transit through the germinal center, B cells can become memory B cells or plasmablasts, which undergo further development to become plasma cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasmablasts are thought to give rise to activated B cell like (ABC) diffuse large B cell lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">
          "Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'Cell of Origin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasma cells are thought to give rise to multiple myeloma. (See
         <a class="medical medical_review" href="/z/d/html/6660.html" rel="external">
          "Multiple myeloma: Pathobiology", section on 'Cell of origin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H38692684">
         <span class="h2">
          T cell or NK cell lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         T and NK cell lymphomas can arise at any stage of normal T or NK cell development. As described above, NK cells share phenotypic and functional features with gamma/delta T lymphocytes making the distinction between tumors derived from these cells difficult. For cases in which this distinction is unclear, the term "NK/T cell" NHL is used.
        </p>
        <p>
         Normally, prothymocytes reside in the bone marrow and produce lymphoid progenitors that travel to the thymus and undergo positive and negative selection resulting in mature, antigen-naïve T cells. The T cell receptor (
         <em>
          TCR
         </em>
         ) genes are rearranged during this process resulting in a heterodimeric receptor made of either alpha and beta (also called TCR2) or gamma and delta (also called TCR1) chains. Alpha/beta T cells are released from the thymus as CD4 positive or CD8 positive naïve T cells. Antigen exposure stimulates their transformation into T lymphoblasts which then become effector cells, memory cells, or follicular helper T cells of germinal centers. In contrast, gamma/delta T cells undergo little cellular expansion within the thymus but may expand considerably in the periphery. NK cells develop in the bone marrow and travel to the spleen, mucosa, and peripheral blood without maturing in the thymus. (See
         <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">
          "T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thymic T cells are thought to give rise to lymphoblastic T cell NHL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Post-thymic T cells and NK cells are thought to give rise to the other peripheral T cell NHLs.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4026687">
         <span class="h1">
          PATHOGENETIC MECHANISMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other malignancies, the pathogenesis of lymphomas is a complex process involving progressive accumulation of genetic lesions that affect oncogenes and tumor suppressor genes. In some cases, there is a genetic predisposition for the development of certain NHL subtypes (eg, familial chronic lymphocytic leukemia/small lymphocytic lymphoma [CLL/SLL]). In addition, the lymph node microenvironment, which includes stromal cells, macrophages, regulatory T cells, and the lymph node vasculature, has been implicated in the promotion of lymphomagenesis [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Important mechanisms that contribute to lymphomagenesis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Balanced chromosomal translocations
         </strong>
         – The genome of most types of lymphoma is characterized by balanced chromosomal translocations that are often strongly associated with a disease subtype. As an example, t(11;14), which is frequently found in mantle cell lymphoma is associated with overexpression of cyclin D1 [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Balanced translocations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unbalanced chromosomal alterations
         </strong>
         – Unbalanced chromosomal alterations are often recognized by genomic sequencing; such alterations are often associated with tumor progression and adverse outcomes. CLL/SLL, in particular, is typically associated with unbalanced genetic abnormalities [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Unbalanced chromosomal abnormalities'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Somatic mutations
         </strong>
         – Some somatic mutations are present in all cells of the lymphoma (suggesting that they are early pathogenic events); those considered important contributors to lymphomagenesis are often referred to as "driver mutations." Other mutations are found in only a subset of the lymphoma cells, suggesting that they may be acquired as a later step in pathogenesis or as a progression event [
         <a href="#rid5">
          5-7
         </a>
         ]. Examples of characteristic mutations associated with NHL are described below. (See
         <a class="local">
          'Somatic mutations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epigenetic modifications
         </strong>
         – Mutations often affect genes that regulate histone modifications, including
         <em>
          MLL2, MEF2B, EZH2,
         </em>
         and
         <em>
          CREBBP
         </em>
         in DLBCL [
         <a href="#rid8">
          8,9
         </a>
         ], and
         <em>
          CREBBP, EP300,
         </em>
         and
         <em>
          MLL2
         </em>
         in follicular lymphoma [
         <a href="#rid5">
          5,10
         </a>
         ]. Mutations in
         <em>
          CREBBP
         </em>
         for example are loss-of-function events that lead to depletion of H3K27 acetylation and silencing of genes involved in B cell signaling and immune response [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Some features of lymphomagenesis differ from mechanisms associated with solid tumors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The lymphoma genome is relatively stable during most stages of NHL development, whereas many solid tumors (especially epithelial tumors) are associated with apparently random genomic instability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microsatellite instability (a hallmark of defects in DNA mismatch repair genes) has been described in only a small percentage of lymphomas (especially those arising in the context of immunodeficiency [
         <a href="#rid12">
          12
         </a>
         ]), whereas it is more commonly associated with sporadic solid tumors and especially some hereditary syndromes that predispose to developing cancer [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1966934787">
         <span class="h1">
          CHROMOSOMAL TRANSLOCATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1508017932">
         <span class="h2">
          Balanced translocations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chromosomal translocations represent the genetic hallmark of lymphoid malignancies. Most NHL-associated translocations represent reciprocal and balanced recombination between two specific chromosomes, which are recurrently associated with a given tumor type and are clonally represented in each affected patient. (See
         <a class="medical medical_review" href="/z/d/html/4490.html" rel="external">
          "Chromosomal translocations, deletions, and inversions"
         </a>
         .)
        </p>
        <p>
         The most frequent cytogenetic abnormalities have been characterized at the molecular level, leading to the identification of genes that are altered in B cells or T cells, and can cause tumors in transgenic animal models. Most of these genetic lesions selectively associate with specific NHL subtypes, thus representing markers of potential diagnostic significance [
         <a href="#rid14">
          14,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4500.html" rel="external">
          "Genetic abnormalities in hematologic and lymphoid malignancies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4482.html" rel="external">
          "General aspects of cytogenetic analysis in hematologic malignancies"
         </a>
         .)
        </p>
        <p>
         The common feature of all chromosomal translocations associated with NHL is the presence of proto-oncogenes in proximity to the chromosomal recombination sites. In most cases, the structure of the proto-oncogene, and in particular its coding domain, is not affected by the translocation. However, the pattern of expression of the gene is altered by juxtaposition of heterologous regulatory sequences derived from the partner chromosome (proto-oncogene deregulation). Two distinct types of proto-oncogene deregulation may occur:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Homotopic deregulation occurs when the chromosomal translocation alters the pattern of a proto-oncogene normally expressed in lymphocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heterotopic deregulation occurs when a proto-oncogene normally not expressed in lymphoid cells is ectopically expressed in the lymphoma.
        </p>
        <p>
        </p>
        <p>
         In most types of NHL-associated translocations, the heterologous regulatory regions responsible for proto-oncogene deregulation are derived from antigen receptor loci, which are expressed at high levels in the target tissue.
        </p>
        <p>
         An alternative mechanism of oncogene activation by chromosomal translocation is the juxtaposition of two genes to form a chimeric gene coding for a novel chimeric protein. This mechanism, which is common in chromosomal translocations associated with acute myeloid leukemia and chronic myeloid leukemia, is not associated with NHL, with the exception of t(2;5)(p23;q35) as found in the NHL variant, anaplastic lymphoma, and t(11;18) as found in extranodal marginal zone lymphoma [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)", section on 'Pathogenesis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"
         </a>
         .)
        </p>
        <p>
         Molecular cloning of the loci involved in the translocations most frequently associated with NHL has led to the identification of a number of proto-oncogenes involved in lymphomagenesis. The structural and functional consequences of each chromosomal translocation associated with NHL are described separately in the context of the molecular pathogenesis of the various NHL subtypes.
        </p>
        <p class="headingAnchor" id="H2217003051">
         <span class="h2">
          Unbalanced chromosomal abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         The current model of lymphoma pathogenesis suggests that balanced translocations are the initiating events, while unbalanced chromosomal gains and losses are likely to be associated with clonal evolution that occurs with disease progression. Studies in follicular lymphoma have found an average of four to eight additional chromosomal abnormalities in addition to the characteristic t(14;18) [
         <a href="#rid17">
          17,18
         </a>
         ]. Many of these occur at specific reproducible chromosomal locations and, in the case of amplifications, have been associated with increased expression of genes in that region [
         <a href="#rid19">
          19
         </a>
         ]. Loss of 6q has been found in multivariate analysis to predict poor survival in follicular lymphoma [
         <a href="#rid20">
          20
         </a>
         ], but as with most of the unbalanced chromosomal abnormalities, the gene involved is as yet unknown. (See
         <a class="medical medical_review" href="/z/d/html/16646.html" rel="external">
          "Pathobiology of follicular lymphoma", section on 'Other genetic lesions'
         </a>
         .)
        </p>
        <p>
         Recurrent and subtype-specific NHL variants associated with specific chromosomal deletions suggest that loss of currently unidentified tumor suppressor genes contribute to lymphomagenesis [
         <a href="#rid17">
          17
         </a>
         ]. The most frequent of these deletions involves the long arm of chromosome 6 (6q) [
         <a href="#rid21">
          21
         </a>
         ]. In some cases, 6q deletion is the sole cytogenetic abnormality and is often associated with poor prognosis [
         <a href="#rid3">
          3
         </a>
         ]. Deletions of chromosome 13q14 represent the most frequent lesion in CLL/SLL, occurring in more than half of cases [
         <a href="#rid22">
          22
         </a>
         ]. Mapping studies have determined that the minimal region of deletion does not include the retinoblastoma tumor suppressor gene, which is also located on chromosome 13q14, but rather is focused on MIR15-16 [
         <a href="#rid22">
          22
         </a>
         ]. These micro-RNA genes, such as miR-15a or miR-16-1, may also act as tumor suppressors [
         <a href="#rid23">
          23,24
         </a>
         ]. MicroRNAs are small conserved noncoding RNAs that downregulate their target genes by specifically decreasing their mRNA levels [
         <a href="#rid25">
          25
         </a>
         ]. The B cell leukemia/lymphoma 2 (Bcl-2) gene is thought to be a target of miR-15a/miR16-1. (See
         <a class="medical medical_review" href="/z/d/html/4489.html" rel="external">
          "Staging and prognosis of chronic lymphocytic leukemia", section on 'Complex karyotype'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3383580091">
         <span class="h1">
          SOMATIC MUTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The timing of acquisition of somatic mutations in lymphomas and how they may interact with chromosomal translocations or unbalanced chromosomal abnormalities are still being elucidated for each subtype of lymphoma. In general, some somatic mutations are clonal, ie, present in all cells of the lymphoma, suggesting that they are early pathogenic events. However, many somatic mutations in genes considered to be "drivers," meaning that they are expected to be important to the pathogenesis of the lymphoma, are found in only a subset of the lymphoma cells, suggesting that they may be acquired as a later step in pathogenesis or as a progression event [
         <a href="#rid5">
          5-7
         </a>
         ].
        </p>
        <p>
         Mutations that activate the B cell receptor and NFKB pathways in diffuse large B cell lymphoma (DLBCL) are common in NHLs [
         <a href="#rid26">
          26-28
         </a>
         ]. Less commonly, mutations affect RNA splicing (eg, chronic lymphocytic leukemia/small lymphocytic leukemia [CLL/SLL] [
         <a href="#rid29">
          29,30
         </a>
         ]), the NOTCH pathway (eg, CLL/SLL [
         <a href="#rid30">
          30,31
         </a>
         ] and marginal zone lymphomas [
         <a href="#rid32">
          32
         </a>
         ]), and immune surveillance (eg, inactivating mutations or deletions of beta-2 microglobulin in DLBCL and Hodgkin lymphoma [HL] [
         <a href="#rid33">
          33
         </a>
         ], and copy number variations or structural aberrations leading to upregulation of PD-L1, most notably in HL [
         <a href="#rid34">
          34
         </a>
         ]). Deletions and mutations of the
         <em>
          TP53
         </em>
         tumor suppressor gene, are strongly associated with certain types of NHL (eg, late stages of follicular lymphoma, CLL/SLL, mantle cell NHL, Burkitt lymphoma and other aggressive B cell NHL) and adverse prognosis [
         <a href="#rid35">
          35-38
         </a>
         ]. Inactivation of p53 is often due to point mutation of one allele and/or chromosomal deletion of the second allele, and/or mutation of other pathway members [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H38691446">
         <span class="h1">
          GENOME DAMAGE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The precise mechanism(s) leading to chromosomal translocations in NHL are unknown, although specific translocations might be determined, in part, by the spatial organization of the respective chromosomes within the nucleus of lymphoid cells that are undergoing physiologic changes to their antigen receptor genes [
         <a href="#rid14">
          14
         </a>
         ]. These aberrations might also represent mistakes within the mechanisms involved in antigen receptor gene rearrangements in lymphoid cells. This hypothesis is supported by the observation that most translocations in NHL involve chromosomal breakpoints within immunoglobulin (
         <em>
          Ig
         </em>
         ) loci in B cell NHL and within T cell receptor (
         <em>
          TCR
         </em>
         ) loci in T cell NHL. In B cell NHL, breakpoints within the Ig loci are often located precisely within joining (J) and switch (S) sequences, which normally mediate Ig gene rearrangements during B cell development. Thus, translocations resulting from errors of the enzymatic machinery mediating
         <em>
          Ig
         </em>
         or
         <em>
          TCR
         </em>
         recombinations pathologically join sequences from different chromosomes instead of sequences within the same antigen receptor locus. These errors become apparent only when the consequences of the abnormal recombination provide a selective growth advantage to the cell. In addition, the genome in certain lymphoma subtypes has been altered by the introduction of exogenous genes via a number of oncogenic viruses.
        </p>
        <p>
         The following sections will review the mechanisms by which antigen receptor gene rearrangements and viral infections may increase the risk of lymphoma development.
        </p>
        <p class="headingAnchor" id="H38689713">
         <span class="h2">
          B cell germinal center reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of B cell lymphomas are derived from germinal center or post-germinal center B cells. During the normal germinal center reaction, there are two major genetic modifications, each of which are required for normal immune development, but also place the cell at risk of acquiring additional mutations that may be oncogenic:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Class-switch recombination changes the immunoglobulin heavy-chain from IgM to IgG, IgA, or IgE. (See
         <a class="medical medical_review" href="/z/d/html/3977.html" rel="external">
          "Immunoglobulin genetics", section on 'Class-switching'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somatic hypermutation is the introduction of point mutations and small deletions or insertions, usually affecting the variable regions of immunoglobulin heavy chain genes of germinal center B cells. Somatic hypermutation is a key component to the affinity maturation of the humoral immune response. (See
         <a class="medical medical_review" href="/z/d/html/3977.html" rel="external">
          "Immunoglobulin genetics", section on 'Somatic hypermutation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Under normal circumstances, the variable region of immunoglobulin heavy chain genes (IgV) of germinal center B cells undergoes somatic hypermutation (SHM), introducing point mutations and small deletions or insertions that allow affinity maturation of the humoral immune response [
         <a href="#rid39">
          39
         </a>
         ]. This process requires activation-induced cytidine deaminase (AID), a mutation-generating enzyme [
         <a href="#rid40">
          40
         </a>
         ]. The genomic instability created by this somatic hypermutation process may also be responsible for the generation of chromosomal translocations between oncogenes and the immunoglobulin loci in human B cell lymphomas (see
         <a class="local">
          'Chromosomal translocations'
         </a>
         above) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         BCL6 is thought to be the critical mediator that allows germinal center B cells to tolerate the DNA strand breaks required for SHM and class switching without triggering apoptosis [
         <a href="#rid42">
          42
         </a>
         ]. The normal SHM process in germinal center B cells can also, to a lesser extent, involve
         <em>
          BCL6
         </em>
         itself, as well as other genes [
         <a href="#rid43">
          43,44
         </a>
         ]. Mutations in BCL-6 or chromosomal rearrangements involving BCL-6, perhaps triggered by SHM, appear to contribute to lymphomagenesis in general [
         <a href="#rid45">
          45
         </a>
         ], particularly to the aggressive and highly aggressive lymphomas. (See
         <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">
          "Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma"
         </a>
         .)
        </p>
        <p>
         Aberrant SHM of
         <em>
          BCL6
         </em>
         and other proto-oncogenes, including
         <em>
          PIM1
         </em>
         ,
         <em>
          MYC
         </em>
         ,
         <em>
          PAX5
         </em>
         , and RhoH (
         <em>
          TFF
         </em>
         ), often involves the coding region of these genes, and has also been detected in a large number of lymphomas, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse large B cell lymphoma (DLBCL) (see
         <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">
          "Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'Aberrant somatic hypermutation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary central nervous system diffuse large B cell lymphoma [
         <a href="#rid46">
          46
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AIDS-associated lymphomas, including Burkitt lymphoma and DLBCL, but also seen in primary effusion lymphomas [
         <a href="#rid47">
          47
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">
          "HIV-related lymphomas: Epidemiology, risk factors, and pathobiology", section on 'BCL6 expression'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoclonal post-transplant lymphoproliferative disorders, including DLBCL and BL [
         <a href="#rid48">
          48
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cutaneous B cell lymphomas, including primary cutaneous follicle center lymphoma and primary cutaneous large B cell lymphoma, leg type [
         <a href="#rid49">
          49
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transformation of follicular lymphoma (more commonly) and chronic lymphocytic leukemia (less commonly) to DLBCL [
         <a href="#rid50">
          50
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extranodal marginal zone lymphoma (EMZL) of mucosa associated lymphoid tissues (MALT) and EMZL in transformation to DLBCL [
         <a href="#rid51">
          51
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hodgkin lymphoma, including nodular lymphocyte-predominant and classical variants [
         <a href="#rid52">
          52
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic lymphocytic leukemia [
         <a href="#rid53">
          53
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         These observations confirm that the phenomenon of aberrant somatic hypermutation is more commonly associated with aggressive or transformed NHL variants, but that this mechanism is also seen in Hodgkin lymphoma and some lower grade lymphomas, suggesting a more general mechanism of lymphomagenesis. Some of the hypermutable genes are also susceptible to chromosomal translocations in the same regions, consistent with a role for hypermutation in generating translocations by DNA double-strand breaks. By mutating multiple genes, and possibly by favoring chromosomal translocations, aberrant hypermutation may be a major contributor to lymphomagenesis.
        </p>
        <p class="headingAnchor" id="H38689720">
         <span class="h2">
          T cell receptor gene rearrangement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of T cell lymphomas are derived from post-thymic T cells. During development, T cells undergo gene rearrangement of their T cell receptor (
         <em>
          TCR
         </em>
         ). Gene rearrangement of these antigen-specific receptors is essential for the development of a highly diverse repertoire of TCRs required for an effective immune system, but also places the cell at risk for acquiring potentially oncogenic chromosomal translocations.
        </p>
        <p>
         As with Ig molecules, TCR proteins contain variable, diverse, joining, and constant regions.
         <em>
          TCR
         </em>
         genes rearrange via the same mechanisms and according to the same rules as immunoglobulin (Ig) genes in B cells. However, unlike B cell Ig genes,
         <em>
          TCR
         </em>
         genes do not undergo somatic hypermutation following initial rearrangement. (See
         <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">
          "T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'
         </a>
         .)
        </p>
        <p>
         T cell lymphomas demonstrate characteristic
         <em>
          TCR
         </em>
         gene recombination patterns and translocations between
         <em>
          TCR
         </em>
         loci and proto-oncogenes. This is perhaps best demonstrated in cases of precursor T cell acute lymphoblastic leukemia/lymphoma where about one-third of cases demonstrate chromosomal translocations involving the TCR alpha and delta loci at chromosome 14q11 and beta and gamma loci at 7q34 [
         <a href="#rid54">
          54,55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15773.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma", section on 'Genetic features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38689727">
         <span class="h1">
          VIRUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oncogenic viruses introduce foreign genes into their target cells. Three distinct viruses are associated with the pathogenesis of specific NHL subtypes [
         <a href="#rid56">
          56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epstein-Barr virus (EBV)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human T cell lymphotropic virus I (HTLV-I)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human herpesvirus 8 (HHV-8)
        </p>
        <p>
        </p>
        <p>
         In contrast, HIV infection increases the risk of lymphoma largely related to its immunosuppressive effects rather than through the introduction of oncogenic genes. (See
         <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">
          "HIV-related lymphomas: Epidemiology, risk factors, and pathobiology", section on 'HIV infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38690884">
         <span class="h2">
          Epstein-Barr virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         EBV has been associated with the development of endemic, sporadic, including AIDS-associated Burkitt lymphoma, EBV-positive diffuse large B cell lymphoma, and EBV-positive mucocutaneous ulcer [
         <a href="#rid57">
          57,58
         </a>
         ]. EBV is also implicated in the pathobiology of lymphoma in the setting of immunosuppressive therapy, including after organ transplantation or in the setting of chronic low-dose
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         therapy [
         <a href="#rid14">
          14,59-63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4723.html" rel="external">
          "Pathobiology of Burkitt lymphoma", section on 'Epstein-Barr virus (EBV) infection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">
          "HIV-related lymphomas: Epidemiology, risk factors, and pathobiology", section on 'EBV co-infection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"
         </a>
         .)
        </p>
        <p>
         Upon infection of a B lymphocyte, the EBV genome is transported into the nucleus, where it exists predominantly as an extrachromosomal circular molecule (episome). This process is mediated by the cohesive terminal repeats, which are represented by a variable number of tandem repeat (VNTR) sequences [
         <a href="#rid64">
          64
         </a>
         ]. Because of this heterogeneity, the number of VNTR sequences enclosed in newly formed episomes may differ considerably, representing a constant clonal marker of the episome and, consequently, of a single infected cell [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Evidence for a pathogenetic role of the virus in NHL infected by EBV is circumstantial, but strong:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EBV can significantly alter the growth of B cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EBV-infected lymphomas usually display a single form of fused EBV termini, suggesting that the entire population represents the clonally-expanded progeny of a single infected cell [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphomas that arise after organ transplantation or during chronic
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         therapy will sometimes at least transiently regress following either withdrawal of the immunosuppression that presumably allowed EBV reactivation or use of a variety of anti-viral measures [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">
          "Treatment and prevention of post-transplant lymphoproliferative disorders", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         EBV lymphoproliferations, particularly in the setting of immunodeficiency, can have a heterogeneous polymorphic or monomorphic appearance and may or may not meet the criteria for a lymphoma. EBV-positive polymorphic B-cell LPD, NOS is the term used for such proliferations that cannot be more definitively categorized, while EBV-positive DLBCL, NOS has been defined as an aggressive lymphoma that, by definition, shows &gt;80 percent of the malignant cells expressing EBER.
        </p>
        <p class="headingAnchor" id="H38690891">
         <span class="h2">
          HTLV-I virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with human T-lymphotropic virus, type I (HTLV-I) has been implicated in adult T cell leukemia-lymphoma (ATL) seen in the Caribbean and Japan. ATL is associated with HTLV-I infection of the tumor clone in 100 percent of the cases [
         <a href="#rid67">
          67
         </a>
         ]. HTLV-I induced T cell transformation does not occur through transduction of a viral oncogene or activation of a human proto-oncogene adjacent to the HTLV-I integration site in the T cell genome. Rather, the pathogenetic effect of HTLV-I in ATL seems to be due to the viral production of a transregulatory protein (HTLV-I Tax) that markedly increases expression of all viral genes and transcriptionally activates the expression of certain host genes.
        </p>
        <p>
         This is described in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4697.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38690898">
         <span class="h2">
          HHV-8 virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human herpesvirus 8 (HHV-8) is a novel member of the gamma-Herpesviridae family, closely related to Herpesvirus saimiri and was originally detected in biopsies of AIDS-related Kaposi sarcoma [
         <a href="#rid68">
          68
         </a>
         ]. Among lymphomas, HHV-8 infection is selectively restricted to body-cavity-based lymphomas (eg, or primary effusion lymphoma), where the viral genome is found within the tumor cells in virtually 100 percent of cases [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
         The mechanism of viral carcinogenesis is not fully elucidated, but may involve viral proteins that are homologous to D-type cyclins and/or interleukin-6 [
         <a href="#rid71">
          71,72
         </a>
         ]. This is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4752.html" rel="external">
          "Primary effusion lymphoma", section on 'Pathogenesis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8319.html" rel="external">
          "Human herpesvirus-8 infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38691854">
         <span class="h2">
          HIV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although HIV infection is a risk factor for the development of NHL, HIV itself does not infect the neoplastic cells of AIDS-related lymphomas. The pathogenesis of NHL in the setting of HIV infection is poorly understood, but immune deregulation leading to loss of control of viruses, such as EBV, is thought to play an important role. (See
         <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">
          "HIV-related lymphomas: Epidemiology, risk factors, and pathobiology", section on 'Pathobiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38690905">
         <span class="h2">
          Simian virus 40
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although simian virus 40 (SV-40) is a polyoma virus with oncogenic potential in humans and animals, it likely does not play a role in the pathobiology of NHL. SV-40 nucleic acids have been identified in a large proportion of patients with mesothelioma and some brain cancers. Its actions are thought to result from inactivation of tumor suppressors, including p53 and members of the retinoblastoma family by a peptide known as the SV-40 large T-antigen. (See
         <a class="medical medical_review" href="/z/d/html/4625.html" rel="external">
          "Epidemiology of malignant pleural mesothelioma", section on 'Viral oncogenes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8280.html" rel="external">
          "Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections"
         </a>
         .)
        </p>
        <p>
         Concerns over the potential association between SV-40 and NHL were initially raised because of SV-40 contamination of poliovirus vaccines used in the United States from 1955 to 1963 [
         <a href="#rid73">
          73
         </a>
         ]. However, two epidemiologic studies have cast doubt on the significance of potential exposure to SV-40:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, childhood exposure to SV-40 through receipt of contaminated
         <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">
          poliovirus vaccine
         </a>
         was not associated with increased risk for AIDS-associated NHL [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a population-based case-control study, there was no evidence that SV-40 seropositive individuals were at increased risk for NHL [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H38689705">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Non-Hodgkin lymphoma (NHL) comprises a diverse group of malignant tumors of lymphoid tissues variously derived from the clonal expansion of B cells, T cells, natural killer (NK) cells, or lymphoid precursors. The pathogenesis of lymphomas involves accumulation of multiple genetic lesions affecting proto-oncogenes and tumor suppressor genes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cell of origin
         </strong>
         – A cell of origin has been proposed for each type of NHL based on morphologic, immunophenotypic, and genetic features of the malignant cells, but many cases are not clear cut. (See
         <a class="local">
          'Cell of origin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          B cell lymphomas
         </strong>
         – The vast majority are derived from germinal center or post-germinal center B cells. Major genetic modifications occur during the normal germinal center reaction of B cells. These changes (class-switch recombination and somatic hypermutation) are required for normal immune development, but also place the cell at risk of acquiring additional mutations that may be oncogenic. (See
         <a class="local">
          'B cell germinal center reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          T cell lymphomas
         </strong>
         – Most are derived from post-thymic T cells. Gene rearrangement of T cell receptors (
         <em>
          TCR
         </em>
         ) is essential for the development of a highly diverse repertoire of
         <em>
          TCR
         </em>
         s required for an effective immune system, but also places the cell at risk for acquiring potentially oncogenic chromosomal translocations. (See
         <a class="local">
          'T cell receptor gene rearrangement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenetic mechanisms
         </strong>
         – Lymphomagenesis is linked to chromosomal rearrangements, acquired somatic mutations, genome damage, and escape from immune surveillance. Lymphomas generally have less genome instability than solid tumors. (See
         <a class="local">
          'Pathogenetic mechanisms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chromosomal translocations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Balanced chromosomal translocations
         </strong>
         – Characteristic balanced chromosomal translocations are associated with certain types of lymphoma; many are thought to be initiating events in lymphomagenesis. (See
         <a class="local">
          'Balanced translocations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Unbalanced chromosomal translocations
         </strong>
         – Unbalanced chromosomal gains and losses contribute to development of certain lymphomas and contribute to clonal evolution and disease progression in many lymphomas. (See
         <a class="local">
          'Unbalanced chromosomal abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Somatic mutations
         </strong>
         – Progressive accumulation of mutations that affect oncogenes and tumor suppressor genes are important contributors to lymphomagenesis. Critical "driver mutations" are present in the entire lymphoma clone, while other mutations that contribute to tumor progression may be present in subclones of the lymphoma. Mutations that activate the B cell receptor and NF-kB pathways are common, but other pathways (eg, NOTCH, RNA splicing, p53, epigenetic maintenance, immune surveillance) are also affected. (See
         <a class="local">
          'Somatic mutations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genome damage
         </strong>
         – Rearrangement of antigen receptor genes is critical to maturation of B lymphocytes (ie, B cell receptor) and T lymphocytes (ie, T cell receptor). Genome damage associated with aberrant rearrangements and/or DNA repair contributes to lymphomagenesis. (See
         <a class="local">
          'Genome damage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viruses
         </strong>
         – Three distinct viruses are associated with pathogenesis of specific NHL subtypes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Epstein-Barr virus (EBV)
         </strong>
         – Associated with the development of Burkitt lymphoma, some DLBCLs and lymphoma in the setting of immunosuppressive therapy. (See
         <a class="local">
          'Epstein-Barr virus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Human T cell lymphotropic virus I (HTLV-I)
         </strong>
         – Implicated in adult T cell leukemia-lymphoma (ATL). (See
         <a class="local">
          'HTLV-I virus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Human herpesvirus 8 (HHV-8)
         </strong>
         – Involved in development of body cavity-based lymphomas (eg, primary effusion lymphoma). (See
         <a class="local">
          'HHV-8 virus'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011; 58:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Offit K, Wong G, Filippa DA, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 1991; 77:1508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouillette P, Collins R, Shakhan S, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011; 118:3051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013; 121:1604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 2013; 122:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109:3879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proschek D, Kafchitsas K, Kurth AA, et al. The quality of applied bone cement depends on the chemical composition of the application system. Eur Surg Res 2011; 47:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Vlasevska S, Wells VA, et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov 2017; 7:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duval A, Raphael M, Brennetot C, et al. The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A 2004; 101:5002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gamberi B, Gaidano G, Parsa N, et al. Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas. Blood 1997; 89:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5:251.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood 1995; 86:3905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horsman DE, Connors JM, Pantzar T, Gascoyne RD. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001; 30:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lestou VS, Gascoyne RD, Sehn L, et al. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol 2003; 122:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viardot A, Möller P, Högel J, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol 2002; 20:4523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaidano G, Hauptschein RS, Parsa NZ, et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 1992; 80:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 1997; 42:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Lisio L, Martinez N, Montes-Moreno S, et al. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012; 120:1782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011; 44:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365:2497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012; 209:1537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011; 20:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116:3268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991; 88:5413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82:2289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82:1994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zenz T, Kreuz M, Fuge M, et al. TP53 mutation and survival in aggressive B cell lymphoma. Int J Cancer 2017; 141:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs H, Bross L. Towards an understanding of somatic hypermutation. Curr Opin Immunol 2001; 13:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006; 440:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 1998; 162:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998; 280:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng HZ, Du MQ, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood 1999; 93:2167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008; 40:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montesinos-Rongen M, Van Roost D, Schaller C, et al. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004; 103:1869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 2003; 102:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerri M, Capello D, Muti G, et al. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. Br J Haematol 2004; 127:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dijkman R, Tensen CP, Buettner M, et al. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood 2006; 107:4926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Berra E, Cerri M, et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica 2006; 91:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood 2007; 109:3500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood 2006; 108:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasar S, Kim J, Improgo R, et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat Commun 2015; 6:8866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999; 111:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyons SF, Liebowitz DN. The roles of human viruses in the pathogenesis of lymphoma. Semin Oncol 1998; 25:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           EPSTEIN MA, ACHONG BG, BARR YM. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet 1964; 1:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tao Q, Robertson KD, Manns A, et al. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998; 91:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol 1998; 16:3788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutiérrez MI, Bhatia K, Barriga F, et al. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 1992; 79:3261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subar M, Neri A, Inghirami G, et al. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 1988; 72:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neri A, Barriga F, Inghirami G, et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 1991; 77:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99:3909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Greene WC. Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia. J Clin Invest 1991; 87:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaidano G, Capello D, Fassone L, et al. Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. J Clin Virol 2000; 16:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Järviluoma A, Koopal S, Räsänen S, et al. KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas. Blood 2004; 104:3349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asou H, Said JW, Yang R, et al. Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells. Blood 1998; 91:2475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzo P, Di Resta I, Powers A, et al. Unique strains of SV40 in commercial poliovaccines from 1955 not readily identifiable with current testing for SV40 infection. Cancer Res 1999; 59:6103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engels EA, Rodman LH, Frisch M, et al. Childhood exposure to simian virus 40-contaminated poliovirus vaccine and risk of AIDS-associated non-Hodgkin's lymphoma. Int J Cancer 2003; 106:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engels EA, Viscidi RP, Galloway DA, et al. Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States. J Natl Cancer Inst 2004; 96:1368.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4711 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20393178" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Aggressive lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21261684" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The challenge of the microenvironment in B-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2009370" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21795749" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23297126" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23415222" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23699601" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21804550" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Analysis of the coding genome of diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22343534" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21986340" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The quality of applied bone cement depends on the chemical composition of the application system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28069569" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15047891" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The mutator pathway is a feature of immunodeficiency-related lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9028329" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15803153" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mechanisms of B-cell lymphoma pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15803153" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mechanisms of B-cell lymphoma pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8122112" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7579360" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cytogenetic evolution patterns in non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11241790" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12930384" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12454108" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinicopathologic correlations of genomic gains and losses in follicular lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1356511" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9205107" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12434020" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16251535" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22760782" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19412164" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18323416" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21179087" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Oncogenically active MYD88 mutations in human lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22158541" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22150006" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21642962" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22891273" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22137796" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Combined genetic inactivation ofβ2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20628145" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2052620" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8400281" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : p53 mutations are associated with histologic transformation of follicular lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8400252" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : p53 mutation is associated with progression in follicular lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28614910" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : TP53 mutation and survival in aggressive B cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11228415" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Towards an understanding of somatic hypermutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16400328" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Role of genomic instability and p53 in AID-induced c-myc-Igh translocations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9602370" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Somatic hypermutation in normal and transformed human B cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15577913" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9624052" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10090923" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Nonimmunoglobulin gene hypermutation in germinal center B cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18066064" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : AID is required for germinal center-derived lymphomagenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14592832" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12714522" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15491294" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16507780" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17018394" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17197434" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16614247" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26638776" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10191766" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9446631" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9728596" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The roles of human viruses in the pathogenesis of lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14107961" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9454768" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9850023" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1317726" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2840989" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1847310" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15044644" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Persistence of the Epstein-Barr virus and the origins of associated lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12010788" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1999493" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7997879" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7700311" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10738140" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15271792" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9516148" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10626798" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Unique strains of SV40 in commercial poliovaccines from 1955 not readily identifiable with current testing for SV40 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12800207" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Childhood exposure to simian virus 40-contaminated poliovirus vaccine and risk of AIDS-associated non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15367569" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
